unpopular opinion: most of what gets said here about telehealth is guesswork
Posting this as a discussion rather than a claim: unpopular opinion: most of what gets said here about telehealth is guesswork.
Why "compounded" is not "generic", written out because the confusion is constant.
A generic is an approved product demonstrated to be bioequivalent to a reference. A compounded preparation is made for a patient or, in the case of an outsourcing facility, under a different regulatory route entirely. It carries no equivalence claim and it is not required to demonstrate one.
That is not a quality judgement. Plenty of compounded preparations are made carefully in facilities with real testing programmes. It is a statement about what has and has not been established, and the difference matters when people assume the two are interchangeable.
The five questions worth asking before you commit to any compounded arrangement.
Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing facility. What concentration is on the label. What the beyond-use date is based on. Whether there is potency testing on the finished preparation rather than only on the starting material.
All five are answerable in one email and the pattern of what comes back is more informative than any of the individual answers. An organisation with a quality system finds these questions ordinary.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Happy to answer the boring questions. Those are usually the ones worth asking.
best — the order this archive was captured in
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product.
yannick_petrov is right about the concentration trap. It breaks arithmetic that has been reliable for months.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
Did they name the facility?
Did they name the facility?
This is the distinction the whole board runs on. Everything else follows from it.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
Did they name the facility?
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
ask what the beyond-use date is based on
Small fix — 503B facilities register with the regulator; 503A pharmacies are licensed by the state board. Different mechanisms.
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
What is the beyond-use date and what is it based on?
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
- 1Removed the staff name. Facilities and clinics can be named here;…7 comments in this branch · started by u/prior_auth_pain